Anido says the company is on track to report results from CONNECT-FX, its clinical study of CBD in children and adolescents with Fragile X Syndrome in the second half of 2019. It has completed enrollment in its Phase 2 BELIEVE 1 of ZYN002 to treat epileptic encephalopathy, with top-line results will be reported in the third quarter of 2019.
Investor deep dive
Zynerba Pharmaceuticals’ quest for CBD gel to treat Fragile X syndrome ventures where big pharma fears to tread
Zynerba updates on its two clinical CBD studies
Quick facts: Zynerba Pharmaceuticals
Market Cap: $273.5 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE